A Retrospective Study of First-Line Combination Chemotherapy in Advanced Colorectal Cancer: A Korean Single-Center Experience.
- Author:
Soon Il LEE
1
;
Se Hoon PARK
;
Do Hyoung LIM
;
Keon Woo PARK
;
Jeeyun LEE
;
Joon Oh PARK
;
Young Suk PARK
;
Ho Yeong LIM
;
Won Ki KANG
Author Information
1. Division of Hematology and Oncology, Department of Medicine, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Korea.
- Publication Type:Original Article
- Keywords:
Colonic neoplasms;
Chemotherapy;
Irinotecan;
Oxaliplatin;
Capecitabine
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Camptothecin;
Colonic Neoplasms;
Colorectal Neoplasms;
Deoxycytidine;
Disease Progression;
Drug Therapy, Combination;
Fluorouracil;
Humans;
Leucovorin;
Organoplatinum Compounds;
Retrospective Studies
- From:Cancer Research and Treatment
2011;43(2):96-101
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Fluoropyrimidine-based combination chemotherapy, in combination with either oxaliplatin or irinotecan, has demonstrated efficacy and tolerability in treatment of advanced colorectal cancer (ACC). MATERIALS AND METHODS: Between January 2006 and December 2007, a total of 478 ACC patients were treated with combination chemotherapy in first-line settings. Combination therapies included: 5-fluorouracil, folinic acid plus oxaliplatin (FOLFOX, n=172), 5-fluorouracil, folinic acid plus irinotecan (FOLFIRI, n=95), capecitabine plus oxaliplatin (XELOX, n=155), and capecitabine plus irinotecan (XELIRI, n=56). FOLFOX and FOLFIRI were repeated every 2 weeks, whereas XELOX and XELIRI were repeated every 3 weeks until occurrence of disease progression or unacceptable toxicity, or until a patient chose to discontinue treatment. RESULTS: The median age was 58 years (range, 19 to 84 years) and the median chemotherapy durations for FOLFOX, FOLFIRI, XELOX, and XELIRI were 4.9, 4.5, 5.7, and 5.4 months, respectively. Combination chemotherapy regimens were generally well tolerated. The estimated median progression-free-survival (PFS) for all patients was 6.8 months (95% confidence interval, 6.3 to 7.3 months). No statistically significant difference in PFS was found among regimens used as first-line chemotherapy. Sixty percent (n=290) of patients received second or further lines of therapy after failure. CONCLUSION: Fluoropyrimidine-based combination chemotherapy regimens appear to be equally active and tolerable as first-line therapy for ACC.
